Phoenix Molecular Designs

Nov 20, 2019

Phoenix Molecular Designs Initiates its Phase 1/1b Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer

Jun 04, 2019

Phoenix Molecular Designs and WuXi STA Reach Drug Supply Milestone to Support Phase I/Ib Study of PMD-026 for TNBC

Mar 21, 2019

Phoenix Molecular Designs Appoints Magda Marquet, Ph.D. to its Board of Directors

Feb 20, 2019

Phoenix Molecular Designs to Present at BIOCOM's 2019 Global Life Science Partnering Conference

Jan 16, 2019

Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer

Dec 27, 2018

Phoenix Molecular Designs to Present at the Biotech Showcase 2019 Conference

Sep 18, 2018

Phoenix Molecular Designs Raises $2.7M To Develop PMD-026 for Triple-Negative Breast Cancer (TNBC)

Apr 16, 2018

Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND